Nature's randomised trials - PubMed (original) (raw)

Comment

Nature's randomised trials

Aroon Hingorani et al. Lancet. 2005.

No abstract available

PubMed Disclaimer

Comment on

• C-reactive protein and its role in metabolic syndrome: mendelian randomisation study.
  Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G. Timpson NJ, et al. Lancet. 2005 Dec 3;366(9501):1954-9. doi: 10.1016/S0140-6736(05)67786-0. Lancet. 2005. PMID: 16325697

Similar articles

• [Metabolic syndrome].
  Alizadeh Dehnavi R, Tamsma JT. Alizadeh Dehnavi R, et al. Ned Tijdschr Geneeskd. 2005 Oct 15;149(42):2377; author reply 2377-8. Ned Tijdschr Geneeskd. 2005. PMID: 16261723 Dutch. No abstract available.
• Letter regarding article by Ridker et al, "Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?".
  Lloyd-Jones DM, Greenland P. Lloyd-Jones DM, et al. Circulation. 2004 Dec 14;110(24):e532. doi: 10.1161/01.CIR.0000149807.32506.F4. Circulation. 2004. PMID: 15596555 No abstract available.
• [Metabolic and cardiovascular health in mental disorders].
  Birkeland KI. Birkeland KI. Tidsskr Nor Laegeforen. 2010 Feb 11;130(3):285-6. doi: 10.4045/tidsskr.09.1194. Tidsskr Nor Laegeforen. 2010. PMID: 20160775 Norwegian. No abstract available.
• C-reactive protein, inflammation, and cardiovascular disease: clinical update.
  Ridker PM. Ridker PM. Tex Heart Inst J. 2005;32(3):384-6. Tex Heart Inst J. 2005. PMID: 16392225 Free PMC article. Review. No abstract available.
• Metabolic syndrome and cardiovascular disease.
  Citrome L. Citrome L. J Psychopharmacol. 2005 Nov;19(6 Suppl):84-93. doi: 10.1177/0269881105058375. J Psychopharmacol. 2005. PMID: 16280341 Review.

Cited by

• Addressing the credibility crisis in Mendelian randomization.
  Burgess S, Woolf B, Mason AM, Ala-Korpela M, Gill D. Burgess S, et al. BMC Med. 2024 Sep 11;22(1):374. doi: 10.1186/s12916-024-03607-5. BMC Med. 2024. PMID: 39256834 Free PMC article. Review.
• Potential drug targets for osteoporosis identified: A Mendelian randomization study.
  Zhao G, Wang Q, Duan N, Zhang K, Li Z, Sun L, Lu Y. Zhao G, et al. Heliyon. 2024 Aug 19;10(16):e36566. doi: 10.1016/j.heliyon.2024.e36566. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39253131 Free PMC article.
• Gut microbiota and pancreatic cancer risk, and the mediating role of immune cells and inflammatory cytokines: a Mendelian randomization study.
  Chen Z, Wang Z, Bao H, Ma S. Chen Z, et al. Front Immunol. 2024 Jul 25;15:1408770. doi: 10.3389/fimmu.2024.1408770. eCollection 2024. Front Immunol. 2024. PMID: 39119339 Free PMC article.
• Excessive Daytime Napping Increases the Risk of Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and a Mendelian Randomization Study.
  Qiao X, Wang X, Guo L, Pan Q. Qiao X, et al. Nat Sci Sleep. 2024 Jul 24;16:1067-1074. doi: 10.2147/NSS.S468444. eCollection 2024. Nat Sci Sleep. 2024. PMID: 39071543 Free PMC article.
• Body Mass Index and Hypertension as Mediators of the Association Between Age at Menarche and Subclinical Atherosclerosis: A Sex-Specific Mendelian Randomization Analysis.
  Meena D, Huang J, Dib MJ, Chirinos J, Jia M, Chauhan G, Gill D, Elliott P, Dehghan A, Tzoulaki I. Meena D, et al. J Am Heart Assoc. 2024 Jul 16;13(14):e032192. doi: 10.1161/JAHA.123.032192. Epub 2024 Jul 9. J Am Heart Assoc. 2024. PMID: 38979809 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information